SVRA

MKT CAP:$1B

Savara Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.14-$0.50 (-8.87%)

Apr 22, 2026

Company Details

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage ...

CEO

Matthew Pauls

IPO Date

Apr 28, 2017

Website

www.savarapharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$119M

EPS (Diluted)

-$0.53

Free Cash Flow

-$101M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 13, 2026

$0EPS -$0.53

Q4 2025

Mar 13, 2026

$0EPS -$0.13

Q3 2025

Nov 12, 2025

$0EPS -$0.14

Q2 2025

Aug 13, 2025

$0EPS -$0.14

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$6M	-$8M
Q2 22	$0	-$6M	-$9M
Q3 22	$0	-$8M	-$11M
Q4 22	$0	-$8M	-$11M
Q1 23	$0	-$9M	-$12M
Q2 23	$0	-$280.0K	-$12M
Q3 23	$0	-$14M	-$18M
Q4 23	$0	-$66.0K	-$18M
Q1 24	$0	-$1M	-$22M
Q2 24	$0	-$600.0K	-$23M
Q3 24	$0	-$20M	-$26M
Q4 24	$0	-$70.0K	-$31M
Q1 25	$0	-$905.0K	-$28M
Q2 25	$0	-$385.0K	-$31M
Q3 25	$0	$0	-$30M
Q4 25	$0	-$40.0K	-$33M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$8M	-$8M
Q2 22	-$9M	-$9M
Q3 22	-$8M	-$8M
Q4 22	-$9M	-$9M
Q1 23	-$12M	-$12M
Q2 23	-$10M	-$10M
Q3 23	-$13M	-$13M
Q4 23	-$16M	-$16M
Q1 24	-$21M	-$21M
Q2 24	-$22M	-$23M
Q3 24	-$23M	-$23M
Q4 24	-$23M	-$23M
Q1 25	-$27M	-$27M
Q2 25	-$26M	-$26M
Q3 25	-$23M	-$23M
Q4 25	-$25M	-$25M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$5.0K
Q3 22	$4.0K
Q4 22	$0
Q1 23	$4.0K
Q2 23	$225.0K
Q3 23	$43.0K
Q4 23	$24.0K
Q1 24	$10.0K
Q2 24	$21.0K
Q3 24	$3.0K
Q4 24	$9.0K
Q1 25	$3.0K
Q2 25	$15.0K
Q3 25	$2.0K
Q4 25	$2.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-22.7%
Q2 22	—	-10.2%
Q3 22	—	+5.6%
Q4 22	—	+2.2%
Q1 23	—	+50.5%
Q2 23	—	+30.2%
Q3 23	—	+71.3%
Q4 23	—	+62.1%
Q1 24	—	+85.6%
Q2 24	—	+89.8%
Q3 24	—	+46.1%
Q4 24	—	+76.8%
Q1 25	—	+26.5%
Q2 25	—	+35.6%
Q3 25	—	+14.8%
Q4 25	—	+7.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$574.0K	—
Q2 22	$456.0K	—
Q3 22	$450.0K	—
Q4 22	$561.0K	—
Q1 23	$864.0K	—
Q2 23	$958.0K	—
Q3 23	$0	—
Q4 23	$1M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$3M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$0	—
Q4 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$6M	$2M	—
Q2 22	$6M	$3M	—
Q3 22	$8M	$2M	—
Q4 22	$8M	$3M	—
Q1 23	$9M	$3M	—
Q2 23	$9M	$3M	—
Q3 23	$14M	$4M	—
Q4 23	$13M	$5M	—
Q1 24	$17M	$6M	—
Q2 24	$18M	$6M	—
Q3 24	$20M	$6M	—
Q4 24	$23M	—	$8M
Q1 25	$19M	$9M	—
Q2 25	$21M	$11M	—
Q3 25	$21M	$10M	—
Q4 25	$21M	$13M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$79M	$73M	$152M
Q2 22	$95M	$47M	$142M
Q3 22	$120M	$14M	$134M
Q4 22	$52M	$74M	$126M
Q1 23	$34M	$81M	$115M
Q2 23	$23M	$83M	$105M
Q3 23	$28M	$141M	$168M
Q4 23	$27M	$136M	$162M
Q1 24	$17M	$126M	$143M
Q2 24	$24M	$98M	$122M
Q3 24	$21M	$198M	$219M
Q4 24	$15M	$181M	$196M
Q1 25	$20M	$153M	$173M
Q2 25	$17M	$129M	$146M
Q3 25	$16M	$108M	$124M
Q4 25	$33M	$203M	$236M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	153M	+0.1%	+98.4%
Q2 22	153M	+0.0%	+0.2%
Q3 22	153M	+0.0%	+0.1%
Q4 22	153M	+0.0%	+0.1%
Q1 23	153M	+0.0%	+0.0%
Q2 23	153M	+0.0%	+0.0%
Q3 23	164M	+7.6%	+7.6%
Q4 23	180M	+9.4%	+17.7%
Q1 24	183M	+1.5%	+19.5%
Q2 24	183M	+0.0%	+19.5%
Q3 24	212M	+16.0%	+28.9%
Q4 24	198M	-6.4%	+10.2%
Q1 25	216M	+9.1%	+18.4%
Q2 25	216M	+0.1%	+18.5%
Q3 25	216M	+0.0%	+2.2%
Q4 25	222M	+2.7%	+12.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	22
Q2 22	$0	22
Q3 22	$0	22
Q4 22	$0	28
Q1 23	$0	28
Q2 23	$0	28
Q3 23	$0	28
Q4 23	$0	37
Q1 24	$0	37
Q2 24	$0	37
Q3 24	$0	37
Q4 24	$0	59
Q1 25	$0	59
Q2 25	$0	59
Q3 25	$0	59
Q4 25	$0	70

Revenue / Employee